TG Therapeutics, Inc. (TGTX)
-OTC BB 5.65 
0.05(0.88%) 1:46PM EDT
| Prev Close: | 5.70 |
|---|
| Open: | 5.71 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 11.33 |
|---|
| Beta: | 2.64 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 5.60 - 5.72 |
|---|
| 52wk Range: | 1.82 - 6.75 |
|---|
| Volume: | 18,990 |
|---|
| Avg Vol (3m): | 65,450 |
|---|
| Market Cap: | 145.81M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.67 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- TG THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Tue 1:04PM EDT)
- TG Therapeutics, Inc. Announces Presentation of Phase 1 Data for Single-Agent Ublituximab (TG-1101) at the American Society of Clinical Oncology Meeting on June 2, 2013GlobeNewswire(Thu, May 16)
- TG Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- TG THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhEDGAR Online(Tue, May 14)
- TG Therapeutics, Inc. Announces First Quarter 2013 Financial Results and Business UpdateGlobeNewswire(Mon, May 13)
- Stryker Hits New 52-Week HighZacks(Fri, May 10)
- St. Jude Reiterated at NeutralZacks(Fri, May 10)
- TG Therapeutics, Inc. to Host Conference Call on First Quarter 2013 Financial Results and Business UpdateGlobeNewswire(Fri, May 10)
- TG Therapeutics, Inc. to Present at the 12th Annual Needham Healthcare ConferenceGlobeNewswire(Mon, Apr 29)
- TG Therapeutic: A Small-Cap Biotech With Great Potential Growthat Seeking Alpha(Sun, Apr 28)
- TG THERAPEUTICS, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Thu, Mar 21)
- TG Therapeutics, Inc. to Present at the 25th Annual ROTH ConferenceGlobeNewswire(Mon, Mar 18)
- Biotech Stock Mailbag: Delcath, Navidea, Affymax, Ziopharmat TheStreet(Fri, Mar 15)
- TG THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhEDGAR Online(Tue, Mar 12)
- TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results and Business UpdateGlobeNewswire(Tue, Mar 12)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2,574.29 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.68 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.16 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved thera...
View More